Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mometasone Nasal Spray in Seasonal Allergic Rhinitis
NCT01850823Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mometasone furoate nasal spray in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Allergan. Primary endpoints: Reflective Total Nasal Symptom Score at 2 weeks and Superiority of Active Treatment Arms Over Placebo at 2 weeks. Started Feb 2013; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT01850823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850823.